Nucleic Acid Antibody Constructs for Sustained RSV Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody therapies for Respiratory Syncytial Virus (RSV) are limited by high costs, complex manufacturing, and short in vivo half-life, necessitating multiple doses and restricting global accessibility.
Innovation Solution
Development of a nucleic acid molecule encoding synthetic antibodies, such as ScFv anti-RSV DMAb, which is delivered in vivo to generate and secrete protein immunoglobulins, leveraging the body's muscle cells for antigen binding and immune response induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used for RSV prevention, then protection efficacy is improved, but in vivo half-life is limited requiring multiple doses
Solution Approach 1:
The patent applies dynamics by transitioning from static monoclonal antibody administration to dynamic in vivo expression systems. The nucleic acid sequences are delivered to host cells which then dynamically produce antibodies continuously, allowing the system to adapt and maintain protective levels over extended periods without repeated external dosing.
Solution Approach 2:
The patent implements self-service by enabling host cells to autonomously produce the therapeutic antibodies after initial nucleic acid delivery. The body's own cellular machinery is harnessed to synthesize and secrete anti-RSV antibodies, eliminating the need for continuous external antibody administration and extending functional duration.
2Reliability
If monoclonal antibodies are used for RSV prevention, then protection efficacy is improved, but cost and distribution complexity increase
Solution Approach 1:
The patent applies copying by transferring the genetic blueprint for antibody production into host cells rather than administering the actual protein antibodies. The nucleic acid sequences serve as templates that cells replicate and translate into functional antibodies, simplifying distribution since nucleic acids are more stable and easier to manufacture than complex protein therapeutics.
Solution Approach 2:
The patent substitutes the mechanical system of cold-chain storage and complex distribution infrastructure with a biochemical system. Nucleic acid sequences can be stored and transported under simpler conditions, and the body's natural protein synthesis machinery replaces the need for complex manufacturing and distribution of purified antibodies.
3Ease of manufacture
If in vivo expression platform is used, then manufacturing cost is reduced, but immunity duration must be maintained
Solution Approach 1:
The patent ensures continuity of useful action by designing nucleic acid delivery systems that enable sustained in vivo expression. The host cells continuously transcribe and translate the delivered sequences, maintaining antibody production over extended periods. This continuous endogenous synthesis preserves immunity duration while leveraging the cost advantages of nucleic acid-based manufacturing.
Data Source
AI summary
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Respiratory Syncytial Virus antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Respiratory Syncytial virus infection in a subject using the composition and method of generation.